Yahoo · Oct 12, 2026
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.
PM
NASDAQ · PMVP
PMV Pharmaceuticals, Inc.
Healthcare · Biotechnology
$1.33
Down-$0.06 (-3.99%)
Updated Nov 5, 2026, 3:43 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 66.78M
- P/E ratio
- -0.81
- Dividend yield
- 0.00%
- 52-week range
- $1.04 – $1.91
- Volume
- 530.41K
- Avg. volume
- 564.7K
Price performance · PMVP
PMVP price history
1M range · 0 trading sessions · Daily adjusted prices
PMVP does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest PMVP news
The latest Smart Investors Daily articles mentioning PMVP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PMVP research
Overview
Company profile and research snapshot.
Company profile
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $18.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 4, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Oppenheimer | Outperform | — |
| Mar 20, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 20, 2024 | HC Wainwright & Co. | Buy | — |
| May 30, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 7, 2026
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity
PMV Pharmaceuticals is rated Buy, targeting $3â$4/share, driven by Rezatapopt's 46% response rate. Click to read more about the PMVP stock.
Yahoo · Oct 5, 2026
PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
Dr. Eckler brings more than two decades of combined experience in healthcare investing across public and private markets at Samsara BioCapital, ArrowMark, and GMT Capital, and scientific research Company planning NDA submission for accelerated approval of rezatapopt in patients with platinum-resistant/refractory ovarian cancer in first quarter of 2027 PRINCETON, N.J., Oct. 05, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology c
Yahoo · Sep 16, 2026
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
